Search

In Stock

Buy Skyrizi (Risankizumab) Online

DISEASE INDICATIONS: Psoriasis

MANUFACTURER: AbbVie Ltd

USAGE: Subcutaneous

MEDICINE APPROVED BY:

European Medical Agency (EMA)

Food and Drug Administration (FDA)

Therapeutic Goods Administration (TGA)

Skyrizi (risankizumab) is a prescription medication used to treat moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. It is a monoclonal antibody that works by blocking the interleukin-23 (IL-23) pathway, which is involved in the development and progression of psoriasis.

From $14,517.47

Clear
Compare

Skyrizi (risankizumab) is a prescription medication used to treat plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. It is a monoclonal antibody that works by blocking the interleukin-23 (IL-23) pathway, which is involved in the development and progression of psoriasis.

Uses

Skyrizi is used to treat plaque psoriasis in adults. Plaque psoriasis is a chronic autoimmune disease that causes red, scaly patches of skin to form. Skyrizi can help to clear these patches and improve the appearance and comfort of the skin.

Storage Conditions

Skyrizi should be stored in the refrigerator at 36°F to 46°F (2°C to 8°C). Do not freeze. Skyrizi can be kept at room temperature for up to 24 hours.

Mechanism of Action

Skyrizi is a monoclonal antibody that binds to the p19 subunit of IL-23 and blocks its interaction with the IL-23 receptor. IL-23 is a cytokine that plays a key role in the development and progression of psoriasis. By blocking IL-23, Skyrizi can help to reduce inflammation and improve the symptoms of psoriasis.

How to Use

Skyrizi is administered by subcutaneous injection every 12 weeks. The recommended dose is 150 mg. Skyrizi should be injected by a healthcare professional.

Important Safety Information

Skyrizi can increase the risk of serious infections, including tuberculosis. Before starting Skyrizi, your doctor will test you for tuberculosis. Skyrizi can also reactivate latent tuberculosis infection.

Skyrizi can also increase the risk of other side effects, such as:

  • Allergic reactions
  • Inflammatory bowel disease (IBD)
  • Psoriasis worsening
  • Injection site reactions
  • Upper respiratory tract infections
  • Headache
  • Diarrhea
  • Nausea
  • Fatigue

Indications

Skyrizi is indicated for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Precautions

Skyrizi should be used with caution in patients with a history of serious infections, tuberculosis, IBD, or other autoimmune diseases.

Skyrizi should not be used in patients who have a history of severe allergic reactions to Skyrizi or other biologic medications.

Interactions

Skyrizi may interact with other medications, including live vaccines and biologic medications. Be sure to tell your doctor about all of the medications you are taking before starting Skyrizi.

Contraindications

Skyrizi is contraindicated in patients with a history of severe allergic reactions to Skyrizi or other biologic medications.

Overdose

There is no known overdose of Skyrizi.

Side Effects

The most common side effects of Skyrizi are upper respiratory tract infections, headache, diarrhea, nausea, fatigue, and injection site reactions.

More serious side effects of Skyrizi include serious infections, IBD, psoriasis worsening, and allergic reactions.

If you experience any side effects while taking Skyrizi, be sure to tell your doctor.

Additional Information

Skyrizi was approved by the U.S. Food and Drug Administration (FDA) in 2019.

Package

Pre-filled syringe of 150 mg/ml, Pre-filled pen of 150 mg/ml

Reviews

There are no reviews yet.

Write a review

Your email address will not be published. Required fields are marked *

Bestsellers

Buy Skilarence (dimethyl fumarate) Online

From $93.21
(0 Reviews)
DISEASE INDICATIONS: Psoriasis MANUFACTURER: Almirall, S.A. USAGE: Oral MEDICINE APPROVED BY: European Medical Agency (EMA) Skilarence (dimethyl fumarate) is a prescription medication used to treat moderate to severe plaque psoriasis in adults. It is an oral medication that works by suppressing the immune system and reducing inflammation.

Buy Xeljanz : Tofacitinib 5 mg Tablets Online

$417.52
(0 Reviews)
Brand Name: Xeljanz Composition: Tofacitinib Manufactured by: Pfizer Pharmaceuticals, Inc. Strength: 5 mg Form: Tablets Packing: Pack of 60 Tablets Prescription Required *

Buy Takhzyro (lanadelumab) Online

$14,055.70
(0 Reviews)
DISEASE INDICATIONS: Hereditary angioedema (HAE) MANUFACTURER: Shire Pharmaceuticals USAGE: Subcutaneous MEDICINE APPROVED BY: European Medical Agency (EMA) Food and Drug Administration (FDA) Takhzyro (lanadelumab) is a prescription medication used to prevent attacks of hereditary angioedema (HAE) in people 2 years of age and older. HAE is a rare genetic disorder that causes episodes of swelling in the face, throat, abdomen, hands, and feet. These episodes can be life-threatening.

Buy Stelara (ustekinumab) Injection Online

From $5,034.51
(0 Reviews)
Stelara, known by its generic name Ustekinumab, is a prescription medication used in the treatment of certain autoimmune diseases, primarily plaque psoriasis, psoriatic arthritis, and Crohn's disease.

Buy Cibinqo (abrocitinib) Online

From $1,287.82
(0 Reviews)
DISEASE INDICATIONS: Atopic Dermatitis MANUFACTURER: Pfizer Limited USAGE: Oral MEDICINE APPROVED BY: European Medical Agency (EMA) Food and Drug Administration (FDA) Pharmaceuticals and Medical Devices Agency (PMDA) Medicines & Healthcare products Regulatory Agency (MHRA) Cibinqo (abrocitinib) is a prescription medicine used to treat adults and children 12 years of age and older with moderate-to-severe atopic dermatitis (eczema) that did not respond to other treatment and is not well controlled with prescription medicines, including biologics, or when they cannot be tolerated.

Buy Skyrizi (Risankizumab) Online

From $14,517.47
(0 Reviews)
DISEASE INDICATIONS: Psoriasis MANUFACTURER: AbbVie Ltd USAGE: Subcutaneous MEDICINE APPROVED BY: European Medical Agency (EMA) Food and Drug Administration (FDA) Therapeutic Goods Administration (TGA) Skyrizi (risankizumab) is a prescription medication used to treat moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. It is a monoclonal antibody that works by blocking the interleukin-23 (IL-23) pathway, which is involved in the development and progression of psoriasis.

Buy Adbry (tralokinumab-ldrm) Online

$1,283.00
(0 Reviews)
DISEASE INDICATIONS: Atopic Dermatitis MANUFACTURER: Leo Pharma USAGE: Subcutaneous MEDICINE APPROVED BY: Food and Drug Administration (FDA) Adbry (tralokinumab-ldrm) is a fully human monoclonal antibody that neutralizes the activity of interleukin-13 (IL-13), a cytokine that plays a key role in the pathogenesis of atopic dermatitis. Adbry is approved for the treatment of moderate-to-severe atopic dermatitis (AD) in adults and adolescents 12 years of age and older.

Back to Top
Product has been added to your cart